Small Pharma Ltd

Cybin UK Ltd

Kudos Pharmaceuticals Limited

Zogenix International Limited

Cyclacel Pharmaceuticals, Inc.

Derek Londesbrough

Keith Allan Menear

Peter Rands

Marc W Andersen

Zelah Joel

Tiffanie Benway

Martin Francis Jones

Richard Chubb

George Knight

Janette Cheryman

Chris Gill

John Pittam

David Laffan

Alex Hudson

Keith Mullholland

Michal Czyzewski

Anthony Ottridge

Ian Ashworth

Chris Atherton

Benjamin Skead

Michael Hallett

The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neurological disorders. Compounds of formula I comprise at least one deuterium atom at the α-position and consequently have improved oral bioavailability relative to α-diprotic analogues.

Compounds

Syntheses of compounds of Formula III from compounds of Formula I via compounds of Formula II are described, as well as particular compounds of Formula III, or pharmaceutically acceptable salts thereof, compositions comprising such compounds, and uses thereof. For example, certain of these compounds and compositions of Formula III have uses in the treatment of psychiatric or neurological disorders.

Synthesis of N,N-dimethyltryptamine-type compounds, methods, and uses

Syntheses of compounds of Formula III from compounds of Formula I via compounds of Formula II are described, as well as particular compounds of Formula III, or pharmaceutically acceptable salts thereof, compositions comprising such compounds, and uses thereof. For example, certain of these compounds and compositions of Formula III have uses in the treatment of psychiatric or neurological disorders. 

The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neurological disorders. Compounds of formula I comprise at least one deuterium atom at the &#x3b1;-position and consequently have improved oral bioavailability relative to &#x3b1;-diprotic analogues. 

Growing community of inventors

London, United Kingdom

Derek Londesbrough